Impending FDA Guidance Could Offer More Leeway For Diagnostic Studies
This article was originally published in The Gray Sheet
Executive Summary
An imminent FDA guidance document could offer the increased flexibility that in vitro diagnostic study sponsors are seeking for human sample collection